Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, has suggested the potential utility of its lead drug, BOLD-100, as a novel antiviral agent, it was reported on Friday.
The firm is looking for expressions of interest from collaborators who have the capability and resources to allow rapid advancement of BOLD-100 in the treatment of COVID-19.
The product's main mechanism of action is to inhibit stress-induced upregulation of GRP78. GRP78 is a common receptor for viral recognition of host cells and the recent publication by Ibrahim et al entitled 'COVID-19 spike-host cell receptor GRP78 binding prediction' on 10 March 2020 in the Journal of Infection identified GRP78 as a potential binding site for COVID-19. Other published literature has suggested that inhibiting or blocking GPR78 can decrease viral loads or viral replication in Ebola, Japanese Encephalitis Virus and Dengue Virus. The company is focused on development of the product in combination with FOLFOX and other anti-cancer agents for the treatment of various gastrointestinal cancers, including gastric, pancreatic, colorectal and bile duct (cholangiocarcinoma) cancers. An earlier completed Phase one monotherapy study of BOLD-100 in advanced cancers indicated that BOLD-100 was generally well-tolerated, with minimal side effects. Presently, the company has ample cGMP clinical product available and an open IND/CTA in the United States and Canada, respectively, allowing for potentially rapid clinical development.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial